March 2018

Endocyte Completes $86M Shelf-Takedown Public Offering

United States - Minnesota

Endocyte, a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer, completed a $86.2 million shelf-takedown offering of more than 20 million shares of common stock, which included full exercise of the underwriters' greenshoe option. Faegre Baker Daniels advised Endocyte in the offering.

The shares trade on the Nasdaq Global Market under the symbol "ECYT." Jefferies LLC, Wells Fargo Securities, LLC, and Deutsche Bank Securities Inc. acted as joint book-running managers for the offering. Wedbush Securities Inc. acted as co-lead manager for the offering.

The Faegre Baker Daniels website uses cookies to make your browsing experience as useful as possible. In order to have the full site experience, keep cookies enabled on your web browser. By browsing our site with cookies enabled, you are agreeing to their use. Review Faegre Baker Daniels' cookies information for more details.